1. A randomized controlled trial to compare the safety and effectiveness of doxycycline (200 mg daily) with oral prednisolone (0·5 mg kg−1 daily) for initial treatment of bullous pemphigoid: a protocol for the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) Trial. (1st July 2015) Authors: Chalmers, J.R.; Wojnarowska, F.; Kirtschig, G.; Nunn, A.J.; Bratton, D.J.; Mason, J.; Foster, K.A.; Whitham, D.; Williams, H.C.; Williams, H.; Mason, J.; McDermott, M.; Yong, A.; Chriba, M.; Banks‐Dunnell, K.; Butcher, D.; Cox, N.; Nik, M.; Gilbanks, K.; Davies, K. Journal: British journal of dermatology Issue: Volume 173:Number 1(2015:Jul.) Page Start: 227 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A randomized controlled trial to compare the safety and effectiveness of doxycycline (200 mg daily) with oral prednisolone (0·5 mg kg−1 daily) for initial treatment of bullous pemphigoid: a protocol for the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) Trial. (26th May 2015) Authors: Chalmers, J.R.; Wojnarowska, F.; Kirtschig, G.; Nunn, A.J.; Bratton, D.J.; Mason, J.; Foster, K.A.; Whitham, D.; Williams, H.C.; the BLISTER study group; Williams, H.; Mason, J.; McDermott, M.; Yong, A.; Chriba, M.; Banks‐Dunnell, K.; Butcher, D.; Cox, N.; Nik, M.; Gilbanks, K. Journal: British journal of dermatology Issue: Volume 173:Number 1(2015:Jul.) Page Start: 227 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. BSPD guidelines for treatment of IH with propranolol. (17th September 2018) Authors: Solman, L.; Glover, M.; Beattie, P.E.; Buckley, H.; Clark, S.; Gach, J.E.; Giardini, A.; Helbling, I.; Hewitt, R.J.; Laguda, B.; Langan, S.M.; Martinez, A.E.; Murphy, R.; Proudfoot, L.; Ravenscroft, J.; Shahidullah, H.; Shaw, L.; Syed, S.B.; Wells, L.; Flohr, C. Journal: British journal of dermatology Issue: Volume 179:Number 3(2018) Page Start: e146 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. BSPD guidelines for treatment of IH with propranolol. (1st September 2018) Authors: Solman, L.; Glover, M.; Beattie, P.E.; Buckley, H.; Clark, S.; Gach, J.E.; Giardini, A.; Helbling, I.; Hewitt, R.J.; Laguda, B.; Langan, S.M.; Martinez, A.E.; Murphy, R.; Proudfoot, L.; Ravenscroft, J.; Shahidullah, H.; Shaw, L.; Syed, S.B.; Wells, L.; Flohr, C. Journal: British journal of dermatology Issue: Volume 179:Number 3(2018) Page Start: e146 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Current Views on Clinical Oncology Training from the 2015 Oncology Registrars' Forum Survey. Issue 9 (September 2016) Authors: Kosmin, M.; Brown, S.; Hague, C.; Said, J.; Wells, L.; Wilson, C. Journal: Clinical oncology Issue: Volume 28:Issue 9(2016) Page Start: e121 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. EP-1478: Anal cancer VMAT: Lumbosacral plexus DVHs with standard & escalated doses proposed in the ACT5 study. (April 2018) Authors: Samuel, L.; Al-Hajri, T.; Findlay, E.; Wells, L. Journal: Radiotherapy and oncology Issue: Volume 127(2018)Supplement 1 Page Start: S801 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for Paediatric Dermatology consensus guidelines. (1st September 2018) Authors: Solman, L.; Glover, M.; Beattie, P.E.; Buckley, H.; Clark, S.; Gach, J.E.; Giardini, A.; Helbling, I.; Hewitt, R.J.; Laguda, B.; Langan, S.M.; Martinez, A.E.; Murphy, R.; Proudfoot, L.; Ravenscroft, J.; Shahidullah, H.; Shaw, L.; Syed, S.B.; Wells, L.; Flohr, C. Journal: British journal of dermatology Issue: Volume 179:Number 3(2018) Page Start: 582 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for Paediatric Dermatology consensus guidelines3. (17th September 2018) Authors: Solman, L.; Glover, M.; Beattie, P.E.; Buckley, H.; Clark, S.; Gach, J.E.; Giardini, A.; Helbling, I.; Hewitt, R.J.; Laguda, B.; Langan, S.M.; Martinez, A.E.; Murphy, R.; Proudfoot, L.; Ravenscroft, J.; Shahidullah, H.; Shaw, L.; Syed, S.B.; Wells, L.; Flohr, C. Journal: British journal of dermatology Issue: Volume 179:Number 3(2018) Page Start: 582 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P354: REAL-WORLD ANALYSIS OF THE RISKS OF THROMBOTIC AND BLEEDING EVENTS IN PATIENTS RECEIVING PEGYLATED ASPARAGINASE FOR TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA. (23rd June 2022) Authors: Mautner, B.; Brewer, B.; Mort, J.; Pierce, E.; Ghamsari, F.; Dibenedetto, S.; Morse, E.; Wells, L.; Morris, A.; Allen, C.; Patel, I.; D'Souza, D.; Jackson, C.; Perciavalle, M.; Yelvington, B.; Miller, R.; Abernathy, K.; Walsh, K.; Wolfe, H.; Locke, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 254 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P526: REAL-WORLD COMPARISON OF DIFFERENT TREATMENT MODALITIES FOR FAVORABLE RISK ACUTE MYELOID LEUKEMIA: STANDARD DOSE ANTHRACYCLINE VS HIGH DOSE ANTHRACYCLINE VS ADDITION OF GEMTUZUMAB OZOGAMICIN. (23rd June 2022) Authors: Mort, J.; Brewer, B.; Mautner, B.; Dibenedetto, S.; Pierce, E.; Morse, E.; Wells, L.; Ghamsari, F.; Morris, A.; Clark, S.; Reid, J.; Patel, I.; Jackson, C.; Perciavalle, M.; Yelvington, B.; Miller, R.; Abernathy, K.; Wolfe, H.; Locke, S.; Zeidner, J. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 425 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗